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Objectives: Routine histologic examination of resected lymph nodes in patients
with stage I non–small cell lung cancer may underestimate the incidence of
advanced disease. The presence of occult lymph node metastases may predict a
higher risk of recurrence after intended curative resection. The purpose of this study
was to determine the prognostic significance of TP53 and K-ras mutations in histo-
logically determined negative lymph nodes from patients with stage I non–small
cell lung cancer who underwent intended curative surgical resection.
Methods: Between July 1995 and March 1998, clinical data and tissue samples of
primary tumors and lymph nodes were collected in a prospective fashion from 102
patients undergoing resection for non–small cell lung cancer (stage I, n = 55; stage
II, n = 32; stage IIIA, n = 15). TP53 and K-ras mutations were detected by direct
sequencing. If molecular alterations were found in the primary tumor, the corre-
sponding lymph nodes were examined for these same TP53 (by oligonucleotide
hybridization) and K-ras (by allele-specific ligation) mutations.
Results: TP53 mutations were found in 47 of 94 primary tumors (50%), and K-ras
mutations were present in 26 of 55 adenocarcinomas (47%). A total of 134 lymph
nodes from 32 patients with stage I disease were analyzed. In 9 cases (28%) the
same TP53 or K-ras mutations were found in tumor and lymph node specimens,
suggesting occult metastasis. On the basis of nodal location, 7 patients had their dis-
ease upstaged by a single stage and 2 patients by two stages. All 28 patients with
stage II or III disease had pathologically determined positive nodes that were con-
firmed as positive by molecular analysis. Standard histopathologic assessment of
regional lymph nodes failed to detect metastases at levels below 0.9% tumor-spe-
cific mutant TP53 clones per node. No statistically significant difference in disease-
specific or overall survival was observed between patients with stage I disease with
and without molecular lymph node metastases.
Conclusions: Occult lymph node metastases are present in a significant percentage
of patients with stage I non–small cell lung cancer. These data suggest that molec-
ular analysis allows a more accurate assessment of staging. However, larger studies
are needed to determine the clinical role of molecular staging.
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Despite advances in preoperative tech-niques to determine lymph node status,about a third of all patients undergoingsurgical resection for early stage non-small cell lung cancer (NSCLC) ulti-mately die of local recurrence.1 The
5-year survival for localized NSCLC remains one of the
lowest among all solid tumors. Multiple factors, including
delay in diagnosis, the extent of pulmonary resection
(lobectomy versus segmentectomy or wedge resection), the
degree of lymph node sampling or dissection, and the pres-
ence of lymph node or bone marrow micrometastases not
identified on histopathologic section, may contribute to this
poor outcome.
Numerous prognostic factors identified in patients with
NSCLC may enable stratification of patients into subsets
according to risk of recurrence after complete resection.
Pathologic stage, including the presence or absence of
lymph node metastases, is the strongest prognostic factor in
patients with lung cancer. Currently staging relies on
histopathologic identification of malignant cells in regional
lymph nodes. Routine pathologic analysis of resected
lymph node usually consists of the preparation of one or
two sections from the central area of the node, followed by
staining with hematoxylin and eosin for microscopic exam-
ination. Unfortunately, this method is often inaccurate,
because tissue sectioning for microscopy is random and the
threshold for subjective confirmation of tumor presence
would require at least 2% tumor replacement of the total tis-
sue.2 Because clinicians make important treatment deci-
sions based on this limited examination, the number of
patients with nodal metastases presumably is underesti-
mated. Immunohistochemical study of regional lymph node
in patients with NSCLC has demonstrated that 15% to 25%
of patients with negative nodes have their disease under-
staged with routine pathologic assessment. However, it
remains unclear whether the detection of micrometastatic
disease in lymph nodes is clinically important.3-8
During the past decade the development and refinement
of immunohistochemical staining techniques and of the
polymerase chain reaction (PCR) to amplify genetic mater-
ial have led to the use of molecular markers as a novel strat-
egy to predict outcome. Molecular alterations in lung cancer
include both induced expression of specific oncogenes (eg,
K-ras), and loss of tumor suppressor genes (eg, TP53). Ras
is a 21-kd G protein, with 20% to 40% of adenocarcinomas
showing K-ras mutations.9,10 Mutations of TP53, with fre-
quencies greater than 50% in NSCLC and 80% in small cell
lung cancer, can lead to loss of tumor suppressor function,
cellular proliferation, and inhibition of apoptosis.11 These
more common molecular abnormalities in lung cancer are
currently used to develop diagnostic studies for detecting
early disease and to discriminate targets for gene therapy.2
The purpose of this prospective study was to improve the
ability to assign a pathologic stage in NSCLC by detecting
the presence of micrometastatic disease in regional lymph
nodes with common molecular techniques. In addition, the
clinical significance of occult lymph node metastases was
evaluated by determining the influence of micrometastases
on survival.
Methods
Patients
Between July 1995 and March 1998, fresh tumor and lymph node
samples were collected from 134 patients with clinical stage I
NSCLC undergoing surgical resection at The Johns Hopkins
Hospital and the Johns Hopkins Bayview Medical Center,
Baltimore, Md. This study was approved by the institutional
review boards at both institutions. Informed consent was obtained
from all patients before the operation. Any patient who received
preoperative therapy (neoadjuvant chemotherapy and radiation
therapy) was not eligible to participate. Thirty-two patients were
excluded because of a final histopathologic report showing more
advanced disease (IIIB to IV tumors, n = 7), other non-NSCLC
primary lung neoplasm (n = 8), no evidence of tumor (n = 5), pul-
monary metastasis from another primary site (n = 5), or a positive
bronchial or vascular margin (n = 7).
At the time of the primary operation all patients included in this
study were treated with wedge or segmental resection, lobectomy,
bilobectomy, or pneumonectomy according to the tumor location
and the patient’s pulmonary function. Complete resection was
achieved in all cases. Lymph node sampling was performed from
all accessible areas and labeled according to the mapping scheme
of the American Thoracic Society.12 TNM classification and tumor
staging were performed according to the revised International
System for Staging Lung Cancer.1 Fifty-five patients had stage I
tumors, 32 patients had stage II tumors, and 15 patients had stage
IIIA tumors. Patient characteristics for the patients with stage I
disease are shown in Table 1. Portions of the tumor and lymph
node to be used for molecular analysis were immediately frozen at
–80°C. DNA was prepared from all tissues in a separate laboratory
to avoid any possibility of PCR contamination.
Clinical information was collected in a prospective fashion.
These data included time of first recurrence, site of first recur-
rence, and time and cause of death. The molecular study investi-
gators were blinded to all clinical and histopathologic information
until completion of all molecular assays. Routine clinical follow-
up was performed without the knowledge of the molecular data.
Histopathologic Examination
Lymph node specimens were embedded in optimum cold-
temperature medium. The specimens were evenly planed with a
cryostat until a smooth representative lymph node section was pre-
sent. Two sections 7 µm thick were then obtained for hematoxylin
and eosin staining. Thirty 14-µm sections were then taken for
DNA extraction, followed by another two 7-µm sections for hema-
toxylin and eosin staining. An additional thirty 14-µm sections
were also taken for DNA extraction, followed by a final two 7-µm
sections for hematoxylin and eosin staining. The hematoxylin and
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eosin–stained sections taken at three levels from each node were
interpreted by a pathologist in blinded fashion as negative or pos-
itive for the presence of metastatic NSCLC.
Sequencing of the TP53 Gene
A 1.8-kilobase fragment of the TP53 gene (exons 5-9) was ampli-
fied from the fresh-frozen DNA in the primary tumor by PCR. A
500-ng sample of genomic DNA was used in a 25-µL PCR reac-
tion containing 16.6-mmol/L ammonium sulfate, 67-mmol/L
tris(hydroxymethyl)aminomethane (Tris) hydrochloride (pH 8.8),
6.7-mmol/L magnesium chloride, 10-nmol/L β-mercaptoethanol,
1% dimethyl sulfoxide, 1.25 mmol/L of each deoxynucleotide
triphosphate, 0.5 units of Taq DNA polymerase, and 150 ng of
primers 5′-GTA GGA ATT CAC TTG TGC CCT GAC TT-3′ and
5′-CAT CGA ATT CTG GAA ACT TTC CAC TTG AT-3′. PCR
amplification was performed for 35 cycles of 95°C for 30 seconds,
58°C for 90 seconds, and 70°C for 90 seconds, with an extension
at 70°C for 5 minutes during the final cycles. Before cycle
sequencing the presence of an amplified product was confirmed by
running 4 µL of the 25-µL reaction on a 1% agarose gel, followed
by staining with ethidium bromide. The remaining 21 µL was
extracted with phenol and chloroform and was ethanol precipi-
tated. The DNA pellet was resuspended in 15 µL of LoTE
(10-mmol/L Tris hydrochloride [pH 8.8], 0.05-mmol/L ethylene
diamine tetraacetic acid), and 2 µL was used for sequencing each
exon of the TP53 gene.
Direct Sequencing of K-ras Mutations
A 270-bp fragment containing exon 1 of the K-ras gene was
amplified from the tumor DNA of patients with primary adeno-
carcinoma, adenosquamous carcinoma, and large cell carcinoma
of the lung. These histologic cell types have been demonstrated
previously to contain K-ras mutations, whereas squamous cell car-
cinomas only rarely contain these mutations. The genomic DNA
was amplified in reactions similar to that described previously
here for TP53 with primers 5´-ATCGAATTCTGGTGGAG-
TATTTGATAGTG-3´ and 5´-ATCGAATTCCTCATGAAAATG-
GTCAGAGAAAC-3´. After purification of the PCR product, exon
1 of the K-ras gene was cycled-sequenced with the sequencing
primer 5´-ATTCGTCCACAAAATGAT-3´. The products of the
sequencing reactions were then separated by electrophoresis on
denaturing gels, fixed, and exposed to film.
Molecular Probing of Regional Lymph Nodes
Patients found to have TP53 or K-ras mutations in their primary
tumors were selected to have their regional lymph nodes studied
by molecular analysis with oligonucleotide hybridization and a
modified allele-specific ligation assay, respectively.
DNA extracted from the lymph node were used to amplify
exons 5 through 9 of the TP53 gene as described previously here.
These PCR products were next cloned into a phage λ vector and
amplified further in Escherichia coli as described elsewhere.13,14
Between 1000 and 2000 clones were transferred to nylon mem-
branes and hybridized with phosphorus 32–end-labeled oligonu-
cleotide probes (17 or 18 bp) with sequences complementary to
the mutant TP53 sequence found during direct sequencing of the
primary tumor. Thus these probes were unique and specific for the
TP53 mutations in each individual tumor. After hybridization the
membranes were washed stringently at 54°C to 60°C to detect
mutant-specific binding of the probes. The membranes were
exposed to x-ray film; hybridizing plaques identified the presence
of a mutant TP53 gene.2,9 The percentage of mutant TP53–con-
taining cells in each specimen was calculated by counting the
number of labeled plaques and dividing this number by the total
number of plaques that hybridized with the wild-type TP53 probe.
For primary tumor samples with a K-ras mutation, a modified
allele-specific ligation assay was used to analyze regional lymph
nodes for metastatic spread.9 A 270-bp fragment containing exon
1 of this gene was amplified from the primary tumor and each
regional lymph node. The PCR products were extracted as previ-
ously described here. The amplified DNA fragment was used as a
template for the ligation assay, which detects all possible muta-
tions at a given K-ras codon position (12a, 12b, 13a, or 13b). The
presence and the nature of the mutations were determined accord-
ing to the migration of ligation products formed in controlled
experiments from templates with known K-ras mutations.
Statistical Analysis
Survival curves were estimated by the Kaplan-Meier method. Any
differences were analyzed by the log-rank test.
Results
TP53 and K-ras Mutations in Primary NSCLC Tumors
One hundred two primary NSCLC tumors were analyzed for
TP53 and K-ras mutations. TP53 mutations were detected in
47 of 94 (50%) of these primary tumors. This included 18 of
49 adenocarcinomas, 23 of 36 squamous cell tumors, 4 of 6
TABLE 1. Characteristics of 55 patients with stage I disease
Age (y)
Mean 67
Range 40-87
Sex (No.)
Male 31
Female 24
Race (No.)
White 39
African American 14
Asian 1
Hispanic 1
Operative procedure (No.)
Lobectomy 52
Bilobectomy 2
Pneumonectomy 1
Stage (No.)
IA 27
IB 28
Cell type (No.)
Adenocarcinoma 29
Squamous cell carcinoma 21
Large cell carcinoma 5
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large cell carcinomas, and 2 of 3 poorly differentiated tumors
of unspecified cell type. No TP53 mutations were detected in
adenosquamous tumors. Twenty-two of 50 stage I tumors
(44%) contained a TP53 mutation. The frequency of TP53
mutations did not appear to correlate with tumor stage in this
small group of patients (data not shown). In addition to
missense mutations, 6 of the 46 mutations (13%) were
frameshift, deletion, or nonsense (termination) mutations and
would be predicted to encode a truncated TP53 protein that
immunohistochemical analysis usually fails to detect. G to T
transversions were the most common mutations detected.
Mutations at codons 12 and 13 of the K-ras gene were
also detected by direct sequencing. K-ras mutations were
detected in 26 of 55 adenocarcinomas of the lung (47%). K-
ras mutations were not detected in patients with large cell,
adenosquamous, or poorly differentiated carcinomas. Similar
to TP53, the frequency of K-ras gene mutations did not
change with increasing pathologic stage. Forty-three percent
(12 of 28) of the stage I adenocarcinomas contained a K-ras
mutation. The most common K-ras gene mutation was a cys-
teine mutation at codon 12. Seven of the 102 patients had
mutations in both the K-ras and TP53 genes. Therefore a
total of 66 patients had either a TP53 or a K-ras mutation (or
both) that would permit examination of the lymph node for
occult metastasis with one of the two molecular assays.
Lymph Node Micrometastases Detected by Molecular
Techniques
Three hundred lymph nodes from 62 patients (4.8 lymph
nodes/patient) were analyzed with molecular techniques.
Molecular staging of lymph nodes was not possible in 4
cases because material harvested as node did not contain
lymphoid tissue on histologic review or there was a failure
to amplify DNA from lymph node. One hundred eighty-six
lymph nodes from 39 patients (4.8 lymph nodes/patient)
with TP53 mutations were tested with the oligonucleotide
plaque hybridization assay (Table 2). All 23 lymph nodes
with microscopic evidence of metastatic cancer were posi-
tive according to molecular analysis. Twenty of the 163
(12%) histopathologically determined negative lymph
nodes had tumor-specific mutant DNA detected with the
plaque assay. Nine of the 90 (10%) histopathologically
determined negative lymph nodes from the 21 patients with
stage I disease (N0) contained tumor-specific TP53 muta-
tions. Seven of these 21 patients with stage I disease (33%)
had the disease upstaged to stage II (n = 5) or stage III (n =
2) lung cancer because of the molecular analysis (Table 3).
All 33 histopathologically determined negative lymph
nodes from 6 patients with T3 N0 tumors were negative for
tumor-specific TP53 mutations. Eleven of 40 (28%)
histopathologically determined negative lymph nodes from
the 12 patients with either N1 or N2 disease (according to
histopathologically diagnosed lymph node metastases in
other lymph nodes) were positive for TP53 mutant cells
with the plaque assay.
The percentage of TP53 mutant containing clones was
quantitated in 25 lymph nodes (12 histopathologically
determined to be negative and 13 histopathologically deter-
mined to be positive). Only 1 lymph node (0.9% mutant
TP53 clones/wild-type clones) containing fewer than 5%
mutant TP53 clones was detected by light microscopy. The
detection threshold for detection of metastases by light
microscopy of hematoxylin and eosin–stained frozen sec-
tions was between 1% and 4.35% (Figure 1).
One hundred fourteen lymph nodes from 23 patients
whose tumors had K-ras mutations were analyzed with the
mutation ligation assay. All 24 lymph nodes with histologic
evidence of metastatic tumor contained mutant K-ras (Table
4). Tumor-specific K-ras mutations were detected in 2 of 44
TABLE 2. Comparison of histopathologic assessment and
molecular analysis of regional lymph nodes with the TP53
plaque hybridization assay among patients (n = 39) with
NSCLC with TP53 mutation
Molecular assessment No. of
Histopathologic assessment with TP53 plaque assay lymph nodes
Negative Negative 143
Negative Positive 20
Positive Negative 0
Positive Positive 23
Figure 1. Percentages of mutant TP53 clones in histopathologi-
cally determined negative (black bars) and histopathologically
determined positive (white bars) lymph nodes from patients with
NSCLC. Only 1 of 11 lymph nodes with fewer than 4.35% mutant
TP53 clones (dashed line) was detected by standard light
microscopy of hematoxylin and eosin–stained section.
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lymph nodes (4.5%) from 11 patients with stage I tumors.
Two of these 11 patients had the disease upstaged to stage II
on the basis of the mutation ligation assay (Table 3). Overall
11 of 134 histopathologically determined negative lymph
nodes from patients with stage I disease (8.2%) contained
tumor-specific mutations of either TP53 or K-ras. This find-
ing resulted in an increase in stage in 9 of 32 patients with
histopathologically determined stage I disease (28%).
Molecular Staging Analysis and Survival
Sixty-six patients had either a TP53 or K-ras mutation in
their primary tumor and were eligible for molecular staging
and survival analysis. Six patients with T3 N0 tumors were
excluded from the survival analysis. The remaining 60
patients were divided into three groups for analyses of over-
all and disease-specific survival. Median follow-up among
surviving patients was 45 months.
In the first group 23 patients with stage I disease were
found to be lymph node negative by both histologic and
molecular techniques. Nine of these 23 patients died during
follow-up. Four patients died of recurrent lung cancer,
whereas 5 patients died of other causes. One of these
patients died in the immediate postoperative period (day 9)
from a presumed pulmonary embolism. One patient died of
a myocardial infarction 17 months after pulmonary resec-
tion. Three patients died of other nonlung malignancies
(prostate, pancreatic, and esophageal cancer) and had no
evidence of recurrent NSCLC at the time of death. Actuarial
1-, 3-, and 5-year survivals among patients with nodes
found negative by both pathologic and molecular methods
were 78%, 59%, and 59%, respectively. Actuarial 1-, 3-, and
5-year lung cancer–specific survivals among these patients
were 85%, 78%, and 78%, respectively.
The second group consisted of 9 patients with stage I
disease according to pathologic study who had micrometas-
tases in regional lymph node detected by TP53 oligonu-
cleotide hybridization or the K-ras ligation assay. Seven of
these patients had their disease upgraded to stage II with
molecular analysis; the remaining 2 had their disease
upstaged to IIIA. Their cases are summarized in Table 3.
Lobectomy was performed in all these cases. Three of these
patients have died of recurrent NSCLC at 8, 14, and 64
months after resection. Two patients had local recurrence of
cancer at 8 and 48 months and were still alive at 5 years
after adjuvant therapy. Both overall and lung cancer–
specific survivals at 1, 3, and 5 years among these patients
were 89%, 78%, and 78%, respectively.
The final group consisted of 28 patients with TP53 or K-
ras mutant tumors and microscopic N1 or N2 disease
according to both pathologic and molecular analyses.
Operations in this group consisted of 25 lobectomies, 1
bilobectomy, and 2 pneumonectomies. One patient with
stage II squamous cell lung cancer died 14 months after
lobectomy with metastatic colon cancer. Actuarial 1-, 3-,
and 5-year survivals among these patients were 78%, 40%,
and 40%, respectively. Actuarial 1-, 3-, and 5-year lung can-
cer–specific survivals among these patients were 78%,
42%, and 42%, respectively. Five-year disease-specific sur-
TABLE 3. Comparison of histopathologic staging and molecular analysis in patients with stage I NSCLC with lymph node
metastases according to molecular analysis
Lymph node mutation Histopathologic staging Molecular staging
Patient Histologic type TP53 K-ras TNM Stage TNM Stage Site of recurrence
738 Adenocarcinoma Neg Pos T1 N0 IA T1 N1 IIA Local
768 Squamous cell carcinoma Pos Neg T1 N0 IA T1 N2 IIIA Local and distant (died 64 mo)
811 Squamous cell carcinoma Pos Neg T1 N0 IA T1 N2 IIIA Local (died at 14 mo)
821 Adenocarcinoma Pos Neg T1 N0 IA T1 N1 IIA None
901 Squamous cell carcinoma Pos Neg T1 N0 IA T1 N1 IIA None
905 Large cell carcinoma Pos Neg T2 N0 IB T2 N1 IIB Local
943 Squamous cell carcinoma Pos Neg T2 N0 IB T2 N1 IIB Local (died at 8 mo)
1011 Large cell carcinoma Pos Neg T2 N0 IB T2 N1 IIB None
1186 Adenocarcinoma Neg Pos T2 N0 IB T2 N1 IIB None
TABLE 4. Comparison of histopathologic assessment and
molecular analysis of regional lymph nodes with the K-ras
mutation ligation assay among patients (n = 23) with NSCLC
with K-ras mutation
Molecular assessment
with K-ras mutation No. of
Histopathologic assessment ligation assay lymph nodes
Negative Negative 87
Negative Positive 3
Positive Negative 0
Positive Positive 24
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vival among patients with N0 disease according to both
pathologic and molecular methods was significantly longer
(P < .03) than that among patients with microscopic lymph
node metastases according to both pathologic and molecu-
lar methods. No difference in disease-specific survival was
present among patients with lymph node micrometastases
detected by molecular but not pathologic means and the
other two patient groups (Figure 2).
Discussion
Occult locoregional spread of cancer is probably the lead-
ing cause of local recurrence after complete surgical resec-
tion and is an early indicator of subclinical micrometastatic
dissemination. Accurate staging is therefore extremely
important and may result in either more extensive primary
therapy to reduce the risk of local recurrence or systemic
adjuvant therapy with the aim of eliminating these occult
deposits. This study examined the prevalence of tumor-
specific TP53 and K-ras gene mutations in histologically
determined negative regional lymph nodes from patients
with resectable NSCLC. Overall, tumor-specific mutations
were found in 8% of histologically determined negative
nodes. These micrometastases led to an increase in patho-
logic stage for 28% of the evaluated patients with stage I
disease. However, the presence of micrometastases did not
negatively impact survival in this group of patients with
stage I NSCLC.
Several techniques have been used to detect occult tumor
cells in the regional lymph nodes and bone marrow of
patients with NSCLC. Immunohistochemical techniques
have been used to detect either epithelial-specific proteins
(eg, cytokeratin) or abnormal TP53 accumulation. With
these techniques, cytokeratin-positive cells have been
detected in 4% to 17% of the regional lymph nodes from
patients with resected stage I disease, leading to a change in
stage for 15% to 70% of patients.4-7,15 In several studies
cytokeratin-positive cells in regional lymph nodes have
been found to be associated with a decrease in disease-
specific survival.5,7,15 Immunohistochemical methods have
also been used to detect occult metastases in the bone mar-
row of patients with NSCLC. From 22% to 60% of patients
with resectable NSCLC have cytokeratin-positive cells in
the bone marrow at the time of resection.16-20 The presence
of occult bone marrow metastases does not correlate with
the presence of occult lymph node metastases and has also
been associated with a decrease in long-term survival.5,16-20
Immunohistochemical assay has several advantages, includ-
ing applicability in all cases (the vast majority of epithelial
tumors stain positively for cytokeratins), adequate sensitiv-
ity (1 in 105 cells), and easy adaptability to current patho-
logic analysis. However, immunohistochemical assay may
be limited by variation in assay results according to the anti-
bodies used, a low false-positive rate in bone marrow from
control patients, and the presence of subjective interob-
server variation.
Molecular techniques to date have relied on reverse
transcriptase–PCR amplification of epithelium- or tumor-
specific genes to detect occult tumor cells. Several problems
have limited this approach. First, low-level expressions of
both epithelial- and tumor-specific genes (eg, carcinoem-
bryonic antigen, MUC1, erb-b2) are present in normal
lymph nodes.21,22 In addition, pseudogenes similar in
sequence homology to several cytokeratins may produce
false-positive bands in normal lymph nodes, making inter-
pretation difficult.23
This study is the first analysis to use a DNA-based assay
to detect tumor-specific changes in regional lymph nodes
from patients with NSCLC. This approach has been used in
squamous cell carcinoma of the head and neck to detect the
presence of TP53 mutations in the surgical margins and cer-
vical lymph nodes that were histopathologically assessed as
negative.2 More importantly, patients with TP53 muta-
tion–positive margins were found to be at increased risk for
local recurrence. In this study this technique and the K-ras
mutation ligation assay identified tumor-specific mutations
in 8.2% of histopathologically determined negative lymph
nodes from patients with purported stage I disease, leading
to a change in stage for 28% of these patients. These per-
centages are similar to numbers obtained with immunohis-
tochemical methods.4-7,15 Long-term survival was not
Figure 2. Disease-specific survivals for patients with TP53 and/or
K-ras mutations in NSCLC. Disease-specific survival in node-neg-
ative NSCLC according to both pathologic and molecular studies
(dotted line) was significantly (P < .03) longer than in histopatho-
logically determined node-positive (N1 or N2; positive by both
histopathologic and molecular assays) NSCLC (heavy line). No
difference in disease-specific survival was seen between
patients with lymph node micrometastases according to molecu-
lar analysis alone (fine line) and patients with node-negative dis-
ease according to both pathologic and molecular studies.
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diminished among the patients with micrometastases,
although this may reflect the small sample size (n = 9). In
addition, TP53 and K-ras mutations in themselves may neg-
atively affect survival, thereby limiting the ability to detect
a further impact of molecular metastases on survival.10,24
Our laboratory has focused on the use of molecular
assays for the early detection and molecular lymph node
staging of patients with NSCLC. One potential limitation of
this approach is the relatively low prevalence of any single
gene mutation or epigenetic alteration in most cancer types.
With a larger panel of molecular alterations (TP53 muta-
tions, K-ras mutations, p16 methylation, and microsatellite
markers), an evaluable marker was found in 86% of patients
with NSCLC and used to detect tumor cells in bron-
choalveolar lavage fluid taken at the time of surgical resec-
tion.25 These techniques have advantages with respect to
immunohistochemical staining, because they involve less
operator variability and can quantitatively establish the
presence or absence of specific molecular abnormalities at
the DNA level. This technique also enables analysis of the
entire lymph node in a single assay, whereas immunohisto-
chemical assay requires visual or automated analysis of
each individual section. Although step-sectioning of an
individual lymph node can increase the yield of both stan-
dard histopathologic and immunohistochemical analyses,
molecular techniques can still detect tumor-specific muta-
tions in cytokeratin-negative lymph nodes.26
There may be several explanations as to why a difference
in survival was not seen between the group with negative
nodes according to both pathologic and molecular analyses
and those with micrometastasis determined by molecular
assays only. The first is the small study population for both
of these groups. The second is that the markers used in this
study may themselves have a negative impact on survival,
and thus a subset of patients with a worse prognosis may
have been studied. The third is that resection of
micrometastatic disease may translate into better survival
than seen among those with incidental histologic or bulky
N1 and N2 disease.
Finally, the choice to use a lymph node sampling tech-
nique rather than dissection may fail to pick up micrometas-
tases, particularly in nodes not resected. This could account
for the cancer-related deaths in the group with N0 disease
according to both methods. Although the topic of lymph
node sampling versus dissection remains controversial with
standard lung resections, there is recent evidence to show
that there may be a survival advantage in doing this for cer-
tain stages (II and IIIA),27,28 although no study has shown a
benefit in N0 disease. In addition, only 4.8 lymph
nodes/patient were examined in this report. In other studies
that showed a negative survival impact when micrometas-
tases were detected by immunostaining, lymph node tissue
was more available (22.1 lymph nodes/patient in the study of
Maruyama and colleagues3 and 10.2 lymph nodes/patient in
the study of Dobashi and associates7). A more appropriate
application of these molecular techniques may be directed
toward detection of the sentinel nodes,29 which may further
increase the yield and decrease the cost of these assays.
Recent progress in translational research has defined
numerous molecular and biologic markers that may serve as
predictors of survival and may also be used for more accu-
rate postoperative disease staging. These molecular indica-
tors not only will help to predict those at risk for recurrence
of disease but will also further define the roles of primary
and adjuvant therapy. With these and other promising bio-
logic markers, a more precise molecular classification may
someday provide a firm basis for therapeutic decision in
the clinical setting. Further investigation and large multi-
institutional trials are necessary to confirm the use of these
micrometastatic markers as useful primary staging tools.
We thank Giovanni Parmigiania, PhD, for his review of the sta-
tistical analysis in this article.
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Discussion
Dr Thomas A. D’Amico (Durham, NC). The use of molecular
techniques in the staging of malignancy, termed molecular bio-
logic substaging, holds the potential to improve the assessment of
prognosis and the assignment of therapy for patients with NSCLC.
The current TNM staging system for lung cancer tends to under-
stage, and clinical staging is even less accurate than pathologic
staging. Molecular biologic substaging may be applied to the pri-
mary tumor to assess prognosis or chemoresistance and to lymph
nodes, serum, or bone marrow to assess occult metastases.
Ahrendt and colleagues’ study used molecular techniques to
detect occult micrometastases in the lymph nodes of patients with
completely resected NSCLC and attempted to correlate the pres-
ence of micrometastatic disease with prognosis. This study was
well designed and carefully analyzed, and it provides a significant
contribution to the mounting evidence that molecular biologic
substaging will become a critical component in the evaluation and
management of patients with early-stage NSCLC. Unlike many
studies in the literature, this study is particularly valuable because
the analysis was necessarily limited to patients with stage I disease
by the construct of evaluating patients who had histologically
determined N0 disease, emphasizing the relative importance of
biologic staging.
The assessment of occult metastases with molecular markers
requires the detection of factors with a high prevalence in the pri-
mary tumor, either genetic mutations or protein expressions. The
prognostic value of the expression or overexpression of these fac-
tors in the primary tumor is irrelevant. The marker is chosen for its
ability to be detected with a greater sensitivity than routine
histopathologic analysis. Thus the higher its prevalence in the pri-
mary tumor, the greater is a marker’s utility in detecting
micrometastases.
First, Dr Yang, you chose two markers, K-ras, present in 40%
of patients with only adenocarcinoma, and TP53, present in 52% of
patients. In this study only 10% of patients had their disease
upstaged on the basis of TP53 and only 3% on the basis of K-ras.
Have you considered using genetic mutations or other markers with
a greater prevalence, such as epidermal growth factor receptor, pre-
sent in 60% to 80% of patients, or using other techniques to mea-
sure cytokeratins, which are present in more than 70% of patients?
Second, this study assessed micrometastases in lymph nodes,
which represent locally advanced disease and are only a surrogate
marker for distant metastatic disease. Our laboratory has applied
your techniques to the detection of occult metastases. Have you
attempted to detect micrometastases in either the bone marrow or
the serum?
Third, other groups have demonstrated that the presence of
occult micrometastatic disease in lymph nodes is associated with
significant differences in recurrence and cancer-specific survival.
This study did not demonstrate risk stratification according to the
presence of micrometastatic disease. The 5-year cancer-specific
survival for patients with stage I disease with and without
micrometastases was 78%, compared with 42% among patients
with histologically determined positive nodes. Although the sam-
ple sizes and other factors that you mentioned may be important,
are other factors perhaps the real cause, such as the lack of sensi-
tivity of your markers and the insistence on using molecular tech-
niques rather than other techniques that may take advantage of
markers with greater sensitivity?
In the article you suggest that molecular staging may alter the
use of adjuvant therapy for patients with early-stage disease. How
do you propose to test this hypothesis, given the absence of risk
stratification in your study?
In conclusion, Ahrendt and colleagues are to be commended
for this important study. Molecular biologic substaging of patients
with early-stage NSCLC should be investigated to improve the
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accuracy of the TNM staging system in assessing prognosis and to
discriminate patients who may benefit from adjuvant therapy.
Dr Jack A. Roth (Houston, Tex). I congratulate Ahrendt and
colleagues for one of the most comprehensive studies of molecu-
lar markers that has been performed to date. My question is really
about the clinical utility of these studies. Dr Yang, how do you
think this will fit into the practice of thoracic oncologic surgery in
the future? For example, if we knew patients had occult metastases
at the time of operation, we would still go ahead with a resection.
Similarly, if we knew it afterward, we probably would still not
consider adjuvant therapies because these have not been of proven
value. Have you applied these techniques earlier in staging, for
example at the time of mediastinoscopy, or are they applicable for
fine-needle aspiration of primary tumors?
Dr Raphael Bueno (Boston, Mass). My questions addresses
the term micrometastatic disease and whether you can truly call
this micrometastatic given that you did not find cancer cells in the
lymph nodes, nor did you find genetic mutations that are related to
cancer or predisposition toward cancer. Specifically, did you look
at a single lymph node or more than one lymph node per patient?
At which levels of lymph nodes did you look? Did you look at a
tumor itself for the same K-ras and TP53 markers or normal adja-
cent lung tissue to dissect out whether you are truly looking at
tumor cells, as we believe you are, or just at the predisposition of
the tissue toward metastasis? Perhaps these should be called prog-
nostic markers rather than micrometastatic disease.
Dr W. Roy Smythe (Houston, Tex). What we know about the
clonality of tumor cells suggests that the cells that leave the pri-
mary tumor and end up in the lymph nodes and peripheral sites as
metastases often have a different genotype than that of the tumor
itself. Also, this technique may offer no greater sensitivity or
specificity than the more prevalent markers, such as cytokeratins.
Have you considered looking with a wider array of markers to
determine whether the metastatic lesions in the lymph nodes may
have a different genotype than that of the tumor and whether that
actually might be more predictive of prognosis than finding these
mutated sequences alone?
Dr Yang. We have not used other agents such as endothelial
growth factor receptor or cytokeratins. It has not been the thrust or
the focus in the laboratory with Dr Sidransky. Have we used other
surrogate markers for occult metastases in bone marrow and serum?
We have used the same markers, microsatellite markers that were
discovered for bladder and for head and neck tumors off of chro-
mosomes 3p and 3q, and we are starting to look at p16 methylation,
not only in the tumors and lymph nodes but also in the serum. Our
early results, although I cannot give you the exact numbers, indicate
that there is a higher incidence of p16 methylation in the serum.
Why did we not demonstrate a significant survival difference?
I still think that it is because we chose lymph node sampling rather
than dissection. The average number of lymph nodes that we ana-
lyzed per patient was 4.8. If you look at some of the immunohis-
tochemical papers from the Japanese group,3,7 they used upward
of 10 to 22 lymph nodes per patient, and they were able to find a
survival difference. I think that this lower sampling rate probably
is the cause for our lack of a survival difference.
We would like to use this in the future as a test for adjuvant
therapy. To take the devil’s advocate position, we know that adju-
vant therapy probably does not help for N1 disease; however, this
may be a subset of patients with N1 disease that it can help. In
reverse, it probably provides more support for the son of blot trial,
giving it in the neoadjuvant phase rather than after the operation.
As to how this fits into clinical practice, I think that if we go
back to the survey from The American Association for Thoracic
Surgery or Society of Thoracic Surgeons about 8 years ago, 80%
of surgeons still did not do lymph node sampling. Unfortunately I
still see a number of patients who have recurrence who were
treated by outside physicians and whose lymph nodes have not
been sampled. I think that this provides more of an argument for
surgeons who do lung cancer surgery that they must at least sam-
ple lymph nodes, if not move on to dissection, depending on what
the American College of Surgeons Oncology Group trial shows.
We have not used this for fine-needle aspiration or microscopy yet.
We have thought about that.
Whatever available resected lymph nodes were taken were ana-
lyzed. In some cases we did look for pockets of nodes in the sub-
carinal and paratracheal areas. We did not go through a dissection,
but if we did not find any nodes those were not sampled. We first
looked for the K-ras and TP53 mutations, and we were looking for
the same type of mutations in the lymph nodes. So we did not have
to go back and look at the tumor again. Early on we checked for
the same mutations in normal tissue. In the first 10 cases the
results were all negative.
I do agree that there probably are differences in clonality
between bone metastases and serum and local recurrence,
although right now we do not have any data to show that there is a
difference from the mutation sampling.
